TY - JOUR
T1 - Invasive meningococcal disease in Malta
T2 - An epidemiological overview, 1994-2007
AU - Muscat, Mark
AU - Spiteri, Gianfranco
AU - Calleja, Neville
AU - Haider, Julie
AU - Gray, Stephen J.
AU - Melillo, Jackie Maistre
AU - Mamo, Julian
AU - Cuschieri, Paul
PY - 2009/11
Y1 - 2009/11
N2 - Since 1996, Malta has experienced an upsurge of invasive meningococcal disease (IMD) following an almost 30 year period with a negligible number of annually reported cases. We reviewed the 233 IMD cases notified during a 14 year period (1994-2007), and analysed epidemiological and laboratory surveillance data. The crude incidence per 100 000 inhabitants peaked in 2000 at 8.1 [95% confidence interval (CI) 5.7-11.6] and again in 2006 at 8.9 (95% CI 6.4-12.4), thereby placing Malta amongst the countries with the highest incidence of the disease in Europe. Of the total cases, 137 (59 %) were confirmed and 30 (13 %) were classified as probable. However, 66 cases (28 %) had no laboratory evidence of the disease and were classified as possible. Information on the serogroup was available for 114 cases. Serogroup B formed the largest proportion (76 %, n=87) followed by serogroup C (16 %, n=18). B:4:P1.19,15 strains (n=46) predominated throughout the study period since their first identification in 1998. With 28 deaths attributed to IMD, the overall case fatality rate was 12 %. Apart from stressing the importance of maintaining high vigilance for IMD, our findings underscore the importance of enhancing laboratory surveillance of the disease, including characterization of the meningococci. Until vaccines against a broad range of serogroup B meningococci become available for universal use, the main methods of control remain the early treatment of cases and the prevention of secondary cases.
AB - Since 1996, Malta has experienced an upsurge of invasive meningococcal disease (IMD) following an almost 30 year period with a negligible number of annually reported cases. We reviewed the 233 IMD cases notified during a 14 year period (1994-2007), and analysed epidemiological and laboratory surveillance data. The crude incidence per 100 000 inhabitants peaked in 2000 at 8.1 [95% confidence interval (CI) 5.7-11.6] and again in 2006 at 8.9 (95% CI 6.4-12.4), thereby placing Malta amongst the countries with the highest incidence of the disease in Europe. Of the total cases, 137 (59 %) were confirmed and 30 (13 %) were classified as probable. However, 66 cases (28 %) had no laboratory evidence of the disease and were classified as possible. Information on the serogroup was available for 114 cases. Serogroup B formed the largest proportion (76 %, n=87) followed by serogroup C (16 %, n=18). B:4:P1.19,15 strains (n=46) predominated throughout the study period since their first identification in 1998. With 28 deaths attributed to IMD, the overall case fatality rate was 12 %. Apart from stressing the importance of maintaining high vigilance for IMD, our findings underscore the importance of enhancing laboratory surveillance of the disease, including characterization of the meningococci. Until vaccines against a broad range of serogroup B meningococci become available for universal use, the main methods of control remain the early treatment of cases and the prevention of secondary cases.
UR - https://www.scopus.com/pages/publications/70350492793
U2 - 10.1099/jmm.0.011312-0
DO - 10.1099/jmm.0.011312-0
M3 - Review article
C2 - 19589903
AN - SCOPUS:70350492793
SN - 0022-2615
VL - 58
SP - 1492
EP - 1498
JO - Journal of Medical Microbiology
JF - Journal of Medical Microbiology
IS - 11
ER -